10-Q: Astria Therapeutics Advances HAE, AD Programs; Extends Cash Runway

Astria Therapeutics reported increased losses in Q2 2025 but highlighted significant clinical progress for its lead drug candidates, navenibart and STAR-0310, and extended its cash runway into 2028 through a new licensing deal.

Summary

• Net loss for the six months ended June 30, 2025, increased to $66.8 million, up from $44.1 million for the same period in 2024.
• Research and development expenses rose by 47% to $53.7 million for the first six months of 2025, driven by increased activity for navenibart and STAR-0310.
• General and administrative expenses increased by 16% to $19.1 million for the six months ended June 30, 2025.
• Interest and investment income decreased by 32% to $6.1 million for the six months ended June 30, 2025, due to lower interest-earning assets and yields.
• Cash, cash equivalents, and short-term investments totaled $259.2 million as of June 30, 2025.
• The company expects its current cash, along with a recent upfront payment and reimbursements from Kaken Pharmaceutical, to fund operations into 2028.
• A Phase 3 trial (ALPHA-ORBIT) for navenibart in hereditary angioedema (HAE) was initiated in February 2025, with top-line results anticipated in early 2027.
• Positive initial safety and efficacy results from the ALPHA-SOLAR long-term trial for navenibart were reported in June 2025, showing robust attack rate reductions and a favorable safety profile.
• A Phase 1a trial for STAR-0310 in atopic dermatitis (AD) was initiated in January 2025, with early proof-of-concept results expected in Q3 2025.
• A license agreement with Kaken Pharmaceutical Co., Ltd. for navenibart in Japan was signed on August 6, 2025, including a $16.0 million upfront payment and potential future milestones and royalties.

Sentiment

Score: 7

Explanation: While the company reported increased net losses and higher operating expenses, this is typical for a clinical-stage biopharmaceutical company advancing its pipeline. The initiation of a Phase 3 trial for navenibart, positive long-term data for navenibart, and the initiation of a Phase 1a trial for STAR-0310 represent significant clinical progress. The licensing deal with Kaken Pharmaceutical provides a substantial upfront payment and future milestones/royalties, extending the cash runway into 2028, which is a strong positive for liquidity and reduces immediate financing pressure. The risks highlighted are standard for the industry but are well-articulated.

Positives

• Initiation of the ALPHA-ORBIT Phase 3 clinical trial for navenibart in February 2025, a significant step towards potential registration for HAE treatment.
• Positive initial safety and efficacy results from the ALPHA-SOLAR long-term trial for navenibart, demonstrating robust attack rate reductions (92%/97% mean/median reduction in monthly attack rate) and a favorable safety profile.
• The license agreement with Kaken Pharmaceutical Co., Ltd. for navenibart in Japan, which includes a $16.0 million upfront payment, potential additional milestones of $16.0 million, and tiered royalties (mid-teens to 30%), providing non-dilutive funding and market expansion.
• Expected cash runway extended into 2028, providing a longer financial buffer for ongoing clinical development.
• Initiation of the Phase 1a trial for STAR-0310 in January 2025, advancing the second product candidate for atopic dermatitis.
• STAR-0310 demonstrated a differentiated profile at the EAACI conference in June 2025, supporting its potential as a best-in-class OX40 antagonist.

Negatives

• Net loss increased significantly to $66.8 million for the six months ended June 30, 2025, compared to $44.1 million for the same period in 2024.
• Research and development expenses increased substantially by $17.3 million (47%) for the six months ended June 30, 2025, indicating a higher burn rate.
• Interest and investment income decreased by $2.8 million (32%) for the six months ended June 30, 2025, reflecting lower interest-earning assets and yields.
• The company has not generated any product revenues and anticipates continued significant operating losses for the next several years.
• Existing cash, cash equivalents, and short-term investments will not be sufficient to fund the completion of development for any product candidates, necessitating substantial additional future funding.

Risks

• Collaborations, such as the one with Kaken Pharmaceutical, may not lead to the successful development, regulatory approval, or commercialization of product candidates.
• Collaborators may have competing priorities, conflicting incentives, or different views on key decisions, potentially hampering or delaying development and increasing costs.
• Limited control over the amount and timing of resources that collaborators will dedicate to development or commercialization efforts.
• Collaborators may abandon research or development projects and terminate agreements, including funding obligations, prior to or upon expiration of agreed terms.
• Disagreements with collaborators over proprietary rights, contract interpretation, or development course could cause delays, termination, or increased responsibilities and potential litigation.
• Collaborators may not properly maintain or defend intellectual property rights, or may use proprietary information in a way that invites litigation.
• The company will require substantial additional cash to fund ongoing expenses, and adequate financing may not be available on acceptable terms or at all.
• Inability to establish additional collaborations on commercially reasonable terms may force the company to alter development and commercialization plans, or increase expenditures at its own expense.
• Changes in U.S. trade policy, including tariffs and investigations (e.g., Section 232 investigation into pharmaceutical imports), could increase manufacturing costs, cause supply chain disruptions, and delay development.
• Disruptions at the U.S. Food and Drug Administration (FDA) and other government agencies due to funding cuts, personnel losses, regulatory reform, or government shutdowns could negatively impact guidance, review, and approval timelines for product candidates.

Future Outlook

The company anticipates continued significant operating losses for the next several years as it develops its product candidates. It expects its existing cash, cash equivalents, and short-term investments, combined with the Kaken upfront payment and expected reimbursement of Phase 3 program costs, to fund operations into 2028. Top-line results from the ALPHA-ORBIT Phase 3 trial for navenibart are anticipated in early 2027, and early proof-of-concept results from the Phase 1a trial of STAR-0310 are expected in Q3 2025. Substantial additional funding will be required to complete the development and commercialization of its product candidates.

Management Comments

• Our focus is to develop first-choice therapies that improve the health and outcomes of patients with allergic and immunologic diseases.
• We believe that navenibart has the potential to be the market-leading and most patient-friendly chronic treatment option for HAE.
• Our vision for navenibart is to lead the HAE market and become the first-choice preventative treatment for HAE with administration every three and six months with the goal of normalizing the lives of people living with HAE.
• We believe that OX40 inhibition has the potential to treat AD and other diseases.
• Our goal for STAR-0310 is to reduce disease activity, relapse rate, and treatment burden for patients with moderate-to-severe AD.
• We expect that our research and development expenses over the next several quarters will be higher than the prior year periods.

Industry Context

Astria Therapeutics operates in the biopharmaceutical sector, specifically targeting rare allergic and immunologic diseases like hereditary angioedema (HAE) and atopic dermatitis (AD). The HAE market is described as strong and growing, with a remaining unmet medical need despite recent improvements in treatment options. The AD market also has insufficient current options, particularly for moderate-to-severe cases, indicating a need for more effective and patient-friendly treatments. The company's strategy of developing potential 'best-in-class' therapies with differentiated profiles (e.g., long-acting, infrequent dosing) aligns with broader industry trends focusing on improved patient convenience and efficacy in chronic disease management. The licensing deal with Kaken Pharmaceutical for navenibart in Japan reflects a common strategy for biotech companies to expand market reach and secure non-dilutive funding through regional partnerships.

Comparison to Industry Standards

• Navenibart's ALPHA-STAR trial results (91-95% reduction in monthly HAE attack rate, 50-67% attack-free patients over 3-6 months) suggest a competitive profile compared to existing HAE therapies, which include plasma kallikrein inhibitors like Takhzyro (lanadelumab) and Orladeyo (berotralstat), and C1-esterase inhibitors. The potential for Q3M and Q6M dosing regimens aims to differentiate it by offering less frequent administration, a key patient-friendly attribute in the HAE market.
• STAR-0310, as an OX40 antagonist, is entering a competitive atopic dermatitis market with established and emerging treatments. Its differentiated profile, including allosteric inhibition and enhanced disruption of OX40/OX40L signaling, positions it against other OX40 inhibitors and broader AD treatments like Dupixent (dupilumab) and Rinvoq (upadacitinib). The focus on extended half-life for infrequent dosing is a common strategy to improve patient adherence and convenience in chronic AD management.

Corporate Governance

Stakeholder Impact

• **Shareholders:** Potential for dilution from future equity financings, but also potential for significant value creation if product candidates achieve commercial success. The Kaken deal provides non-dilutive funding and validates navenibart's potential.
• **Employees:** Increased stock-based compensation expense and company growth indicate continued investment in human capital. The amended stock incentive plan aims to attract and retain talent.
• **Patients (HAE & AD):** Advancement of navenibart into Phase 3 and STAR-0310 into Phase 1a offers hope for new, potentially best-in-class, and patient-friendly treatment options for debilitating diseases.
• **Creditors:** Increased operating losses and continued reliance on external financing may be a consideration, though the extended cash runway into 2028 provides a degree of stability.
• **Partners (Kaken Pharmaceutical):** The new license agreement establishes a significant partnership for navenibart in Japan, aligning interests in development and commercialization.

Next Steps

• Continue support for all navenibart program activities through completion of the ALPHA-ORBIT Phase 3 trial.
• Continue activities related to the planned ORBIT-EXPANSE long-term trial for navenibart.
• Continue Phase 3 development and testing of drug device combinations for navenibart (autoinjector and pre-filled syringe).
• Complete the ongoing Phase 1a clinical trial of STAR-0310 in healthy subjects.
• Determine next steps for the STAR-0310 program, potentially including a proof-of-concept clinical trial in AD patients, based on Phase 1a results.
• Kaken Pharmaceutical Co., Ltd. will provide support for the ALPHA-ORBIT Phase 3 trial in Japan, be responsible for regulatory submissions in Japan, and reimburse a portion of the navenibart Phase 3 program costs.
• Seek substantial additional funding to complete the development and commercialization of product candidates and support continuing operations and pipeline expansion.

Key Dates

Recommendation

Astria Therapeutics is making significant clinical progress with its lead programs, navenibart and STAR-0310, including the initiation of a Phase 3 trial for navenibart and positive long-term data. The recent licensing agreement with Kaken Pharmaceutical provides a substantial upfront payment and extends the company's cash runway into 2028, mitigating immediate liquidity concerns. However, the company continues to incur significant operating losses, and substantial additional capital will be required to complete development and achieve commercialization. While the clinical momentum is positive, the long development timelines and future funding needs suggest a 'hold' recommendation for seasoned investors, balancing the potential upside with the inherent risks of a clinical-stage biotech.

Keywords

Biopharmaceutical, Hereditary Angioedema, HAE, Atopic Dermatitis, AD, Navenibart, STAR-0310, Clinical Trials, Phase 3, Phase 1a, Plasma Kallikrein Inhibitor, OX40 Antagonist, Drug Development, Biotech, SEC Filing, 10-Q